Evidence map›Paper›PMID 37967742›Full record

ArticleWorld neurosurgery2024

Clinical Implications of Pituitary Adenomas Exhibiting Dual Transcription Factor Staining: A Case Series of 27 Patients.

Ilaria Bove, Stephanie K Cheok, Jeffrey J Feng, Robert G Briggs, Jacob Ruzevick, David J Cote, Ishan Shah, Andrew Little, Edward Laws, Ana Valeria Castro and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World neurosurgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ilaria BoveDepartment of Neurological Surgery, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
Stephanie K CheokDepartment of Neurological Surgery, University of Southern California Keck School of Medicine, Los Angeles, California, USA. Electronic address: cheoky1@gmail.com.
Jeffrey J FengDepartment of Neurological Surgery, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
Robert G BriggsDepartment of Neurological Surgery, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
Jacob RuzevickDepartment of Neurological Surgery, University of Washington, Seattle, Washington, USA.
David J CoteDepartment of Neurological Surgery, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
Ishan ShahDepartment of Neurological Surgery, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
Andrew LittleDepartment of Neurological Surgery, Barrow Neurological Institute, Pheonix, Arizona, USA.
Edward LawsDepartment of Neurological Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Ana Valeria CastroDepartment of Neurological Surgery, Henry Ford Health, Detroit, Michigan, USA.
John CarmichaelDepartment of Endocrinology, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
Mark ShiroishiDepartment of Radiology, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
Kyle HurthDepartment of Pathology, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
Gabriel ZadaDepartment of Neurological Surgery, University of Southern California Keck School of Medicine, Los Angeles, California, USA.

Funding

DNA Methylation and gene expression variations influence pituitary adenoma hormonal function and invasive growthR01CA230328 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZADA, GABRIEL · 2018 to 2022
$2.6M
NCI NIH HHS R01 CA230328
6 · The paper itself

Abstract

objectiveAccording to the 2017 World Health Organization classification of neuro-endocrine tumors, pituitary adenomas (PAs) are classified according to immunoexpression of the pituitary-specific transcription factors (TFs). A small subset of PAs exhibit multiple TF staining on immunohistochemistry and we present a series of 27 pathologically-confirmed cases of dual TF staining PAs (dsTF-PAs), and report clinically relevant implications.

methodsA retrospective chart review of a multi-institutional database of patients with PAs surgically resected between 2008-2021 was performed. PAs expressing immunopositivity 2+ TFs. Patient demographics, neuro-imaging characteristics, histopathologic findings, and clinical data were collected.

resultsTwenty-seven patients had pathologically verified dsTF-PAs, of whom 17 were female (63%), with ages ranging from 20-84 years. Twenty-three (85.2%) patients harbored functional PAs, with acromegaly being the most common functional subtype (86.4%). The most common combination of TFs within a single tumor was PIT-1/SF-1 (85.2%). Six PAs exhibited Knosp cavernous sinus invasion grades of 3 or 4 and the Ki-67 labeling index was ≥3% in 6 patients (24.0%) and all stained for PIT-1/SF-1. Hormonal remission was achieved in 78% of functional dsTF-PAs. No PAs showed evidence of recurrence or progression over the mean follow-up period of 28.5 months.

conclusionsPAs exhibiting dsTF-PAs represent a small but clinically relevant diagnostic subset of PAs according to the 2021 World Health Organization criteria, as a majority are GH-producing. Precise classification using TF staining plays a key role in understanding the biology of these tumors. Favorable outcomes can be achieved in this subset of PAs with evolving TF classification.

Indexed as

AdenomaPituitary NeoplasmsFemaleHumansMaleNeurosurgical ProceduresRetrospective StudiesTranscription FactorsTranscription FactorsDual stainingPituitary adenomaTranscription factorWHO classification

Identifiers

PMID37967742
PMCPMC11032010

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.